Citadel Advisors
AVXL icon

Citadel Advisors’s Anavex Life Sciences AVXL Stock Holding History

Citadel Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
559,435
+445,696
+392% +$1.93M ﹤0.01% 6419
2025
Q4 		$405K Sell
113,739
-81,986
-42% -$502K ﹤0.01% 9514
2025
Q3 		$1.74M Sell
195,725
-126,480
-39% -$1.28M ﹤0.01% 6359
2025
Q2 		$2.97M Buy
322,205
+321,731
+67,876% +$2.75M ﹤0.01% 4994
2025
Q1 		$4.07K Sell
474
-240,432
-100% -$2.27M ﹤0.01% 13920
2024
Q4 		$2.59M Buy
240,906
+215,381
+844% +$1.66M ﹤0.01% 5105
2024
Q3 		$145K Sell
25,525
-421,313
-94% -$2.43M ﹤0.01% 10605
2024
Q2 		$1.89M Buy
446,838
+446,834
+11,170,850% +$1.81M ﹤0.01% 5425
2024
Q1 		$20 Sell
4
-273,306
-100% -$1.54M ﹤0.01% 14454
2023
Q4 		$2.54M Sell
273,310
-301,797
-52% -$2.08M ﹤0.01% 4948
2023
Q3 		$3.77M Buy
575,107
+531,449
+1,217% +$4.23M ﹤0.01% 4104
2023
Q2 		$355K Buy
43,658
+42,400
+3,370% +$363K ﹤0.01% 8672
2023
Q1 		$10.8K Sell
1,258
-191,781
-99% -$1.91M ﹤0.01% 13507
2022
Q4 		$1.79M Sell
193,039
-274,867
-59% -$2.94M ﹤0.01% 5687
2022
Q3 		$4.83M Sell
467,906
-231,813
-33% -$2.45M ﹤0.01% 3932
2022
Q2 		$7M Buy
699,719
+471,144
+206% +$4.46M ﹤0.01% 3203
2022
Q1 		$2.81M Buy
228,575
+195,197
+585% +$2.4M ﹤0.01% 5334
2021
Q4 		$579K Sell
33,378
-33,325
-50% -$633K ﹤0.01% 9337
2021
Q3 		$1.2M Buy
66,703
+34,374
+106% +$684K ﹤0.01% 7686
2021
Q2 		$739K Sell
32,329
-6,894
-18% -$102K ﹤0.01% 9128
2021
Q1 		$586K Sell
39,223
-20,161
-34% -$220K ﹤0.01% 9335
2020
Q4 		$320K Sell
59,384
-8,803
-13% -$46.4K ﹤0.01% 8961
2020
Q3 		$310K Buy
68,187
+53,849
+376% +$232K ﹤0.01% 8076
2020
Q2 		$71K Sell
14,338
-7,886
-35% -$29.8K ﹤0.01% 9154
2020
Q1 		$70K Sell
22,224
-56,029
-72% -$195K ﹤0.01% 8855
2019
Q4 		$203K Buy
78,253
+14,362
+22% +$37.7K ﹤0.01% 8160
2019
Q3 		$202K Sell
63,891
-10,188
-14% -$29.4K ﹤0.01% 8141
2019
Q2 		$249K Buy
74,079
+45,074
+155% +$140K ﹤0.01% 7863
2019
Q1 		$88K Sell
29,005
-31,336
-52% -$74.8K ﹤0.01% 8600
2018
Q4 		$94K Sell
60,341
-5,023
-8% -$11.4K ﹤0.01% 8269
2018
Q3 		$178K Buy
65,364
+25,193
+63% +$71.1K ﹤0.01% 8302
2018
Q2 		$105K Buy
40,171
+17,544
+78% +$49K ﹤0.01% 8218
2018
Q1 		$62K Buy
+22,627
New +$63.9K ﹤0.01% 7862
2017
Q2 		– Sell
-16,293
Closed -$94.2K – 7455
2017
Q1 		$94K Buy
+16,293
New +$84.1K ﹤0.01% 6879
2016
Q3 		– Sell
-26,457
Closed -$111K – 7218
2016
Q2 		$162K Buy
+26,457
New +$128K ﹤0.01% 5971
2016
Q1 		– Sell
-100
Closed -$440 – 6759
2015
Q4 		$1K Buy
+100
New +$712 ﹤0.01% 8606

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's AVXL Position: Q1 2026 in Review

Citadel Advisors increased its Anavex Life Sciences (AVXL) stake by 392% in Q1 2026, buying an estimated $1.93M and bringing the position to 559,435 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #6419.

Citadel Advisors first reported a position in AVXL in Q4 2015 and has held it in 36 quarters since. The position peaked at $7M in Q2 2022. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Citadel Advisors held 559,435 shares of Anavex Life Sciences worth $1.72M as of Q1 2026.
  • Citadel Advisors bought 445,696 Anavex Life Sciences shares in Q1 2026, an estimated $1.93M.
  • Anavex Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6419 holding.
  • Citadel Advisors first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 36 quarters since.
  • Citadel Advisors's Anavex Life Sciences position peaked at $7M in Q2 2022.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.